Clinical value of transrectal ultrasound-guided prostate biopsy
Objective To evaluate the clinical value of transrectal ultrasound-guided prostate biopsy.Methods Sixty patients underwent 10 core prostate biopsy guided by transrectal ultrasound(TRUS) from January 2011 to January 2012.Results In 60 patients,the detection rate of prostate cancer were 53.3%(32/60).The display rates of prostate nodule by TRUS increased with the rising of prostate-specific antigen(PSA) levels(Z=-2.9971,P=0.0014).There was significantly different in display rates of prostate nodule of different PSA levels(χ2=9.3854,P=0.0246);The positive rates of biopsy increased gradually with the rising of PSA levels(Z=-4.3657,P0.0001).There was significantly different in the pathological results of different groups(χ2=42.1727,P0.0001).Conclusion The display of prostate nodule by TRUS increases with the rising of PSA levels.The detection rates of prostate cancer are positively correlated with PSA levels.The transrectal ultrasound-guided prostate biopsy has many advantages,such as more safety and less side effects,which will be valuable to the clinic.